Results 121 to 130 of about 77,084 (260)

BCLX_L blockade rewires cell fate to overcome PARP inhibitor resistance in ovarian cancer. [PDF]

Signal Transduct Target Ther
Venkatachalam A, Strathman AR, Hou X, Correia C, Meng XW, McGehee CD, Balczewski EA, Duffield LN, Rossman OK, Wong C, Dai H, Hurley RM, Wagner JM, Singh S, Flatten KS, Peterson KL, Schneider PA, De Lorenzo SB, Larson MC, Oberg AL, Wahner Hendrickson AE, Wu X, Pandey A, Li H, Weroha SJ, Kaufmann SH.   +25 more
europepmc   +1 more source

Hsp90 Inhibition on the Western Blot: N‐Terminal Versus C‐Terminal Inhibitors in Breast Cancer

Medicinal Research Reviews, EarlyView.
ABSTRACT Heat shock protein 90 (Hsp90) is an established and clinically validated anticancer target. By regulating the folding and maturation of diverse client proteins, it is indirectly involved in carcinogenesis. Key breast cancer oncogenic drivers, including estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2, are ...
Jaka Dernovšek, Jernej Cingl, Urša Pečar Fonović, Tihomir Tomašič   +3 more
wiley   +1 more source

AI‐Driven Rational Design of Nanotherapeutics for Pancreatic Ductal Adenocarcinoma

Medicinal Research Reviews, EarlyView.
ABSTRACT Pancreatic ductal adenocarcinoma (PDAC) remains a formidable malignancy characterized by late diagnosis, high recurrence rates, and pronounced chemoresistance. While nanoparticle‐based drug delivery systems (NDDS) offer theoretical advantages over conventional therapies, their clinical translation in PDAC has been severely limited.
Seohyun Choo, Kaeun Chae, Jueun Lee, Inseon Kim, Seunghun S. Lee   +4 more
wiley   +1 more source

Periodontitis and atherosclerotic cardiovascular disease: A critical appraisal

Periodontology 2000, EarlyView., 2023
Abstract In spite of intensive research efforts driving spectacular advances in terms of prevention and treatments, cardiovascular diseases (CVDs) remain a leading health burden, accounting for 32% of all deaths (World Health Organization. “Cardiovascular Diseases (CVDs).” WHO, February 1, 2017, https://www.who.int/news‐room/fact‐sheets/detail ...
Maria Clotilde Carra, Hélène Rangé, Giuseppina Caligiuri, Philippe Bouchard   +3 more
wiley   +1 more source

Functional biomarkers complementing static BRCA/HRD testing for dynamic PARP inhibitor therapy in ovarian cancer: a narrative review. [PDF]

Front Oncol
Wu T, Zhang P, Xi R, Wang X, Hu L, Shen Y, Tao K, Lu J, Wang G.   +8 more
europepmc   +1 more source

Repurposing antimicrobial agents for neuroprotection: Mechanisms, clinical potential, and challenges

Neuroprotection, EarlyView.
Antimicrobial agents exert neuroprotective effects through modulation of interconnected pathways. Tetracyclines, macrolides, antimalarial agents, sulfones, and antiparasitic agents suppress neuroinflammation, oxidative stress, and apoptosis while preserving mitochondrial function and neurotransmission.
Mohammad Amin Manavi, Mohammadreza Salehi, Razieh Mohammad Jafari, Ramin Goudarzi, Saman Khosravi, Ahmad Reza Dehpour   +5 more
wiley   +1 more source

Docosahexaenoic Acid Enhances the Cytotoxic Effects of Enzalutamide and the PARP Inhibitor in Castration-Resistant Prostate Cancer Cell Lines. [PDF]

Int J Mol Sci
da Silva ADT, Ferreira LDP, Ribeiro DL, Tamarindo GH, Góes RM.   +4 more
europepmc   +1 more source

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

Precision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan, Bushra Waheed, Rani Akbar, Daniel Dubwa   +3 more
wiley   +1 more source

Combination of PARP inhibitor olaparib and a vascular disrupting agent reduces tumor growth in a preclinical model of prostate cancer. [PDF]

Cancer Chemother Pharmacol
Sereti E, Evans-Axelsson S, Törnell J, Rehnmark S, Högberg M, Bjartell A.   +5 more
europepmc   +1 more source

Real‐World HRR Testing Pathways and Patterns of Detected Alterations in Prostate Cancer From the Multinational ARON‐3 Study

The Prostate, EarlyView.
ABSTRACT Background Homologous recombination repair (HRR) testing is increasingly relevant in prostate cancer because it identifies patients who may benefit from biomarker‐guided treatment strategies, including poly(ADP‐ribose) polymerase inhibitors (PARPi).
Lorena Incorvaia, Veronica Mollica, Ondřej Fiala, Kazutoshi Fujita, Yüksel Ürün, Bohuslav Melichar, Javier Molina‐Cerrillo, Teresa Alonso‐Gordoa, Umberto Basso, Maria T. Bourlon, Emmanuel Seront, Ugo De Giorgi, Maria José Juan Fita, Pasquale Rescigno, Tarek Taha, Fernando C. Maluf, Alexandr Poprach, Simona De Summa, Tomas Buchler, Luca Galli, Jindrich Kopecky, Gaetano Aurilio, Jakub Kucharz, Carlo Messina, Gabriel Berlingieri Polho, Sarah Scagliarini, Francesco Grillone, Diogo Assed Bastos, Luigi Formisano, Gian Paolo Spinelli, Alessandra Mosca, Alessandro Rizzo, Aristotelis Bamias, Fernando Sabino Marques Monteiro, Andrey Soares, Francesco Massari, Andrew J. Armstrong, Matteo Santoni   +37 more
wiley   +1 more source